Myocardial Damage, Inflammation and Thrombin Inhibition in Unstable Coronary Artery Disease
2003 (English)In: European Heart Journal, ISSN 0195-668X, E-ISSN 1522-9645, Vol. 24, no 1, 86-93 p.Article in journal (Refereed) Published
Unstable coronary artery disease (CAD) is a multifactorial disease involving both thrombotic and inflammatory processes. We have assessed the time-course and the influence of thrombin inhibitors on changes in fibrinogen and C-reactive protein levels, and their relation to myocardial ischaemia in unstable CAD.
METHODS AND RESULTS:
Three hundred and twenty patients were randomized to 72 h infusion with three different doses of inogatran, a direct thrombin inhibitor, or unfractionated heparin. There were no significant differences between the treatment groups in fibrinogen or C-reactive protein levels. Overall, the fibrinogen levels were significantly increased in the first 24-96 h and still elevated at 30 days. The C-reactive protein levels showed a more pronounced increase during the first 24-96 h, but then markedly decreased over 30 days. Troponin-positive compared to troponin-negative patients had higher fibrinogen and C-reactive protein levels up to 96 h, although there was an increase compared to pre-treatment levels in both groups. A high fibrinogen level (pre-treatment top tertile) was associated with an increased rate of death or myocardial (re-)infarction at 30 days, 13% vs 5.6%, P=0.03, and increased long-term mortality. A high C-reactive protein level was related to increased 30-day mortality, 4% vs 0%, P=0.01.
Myocardial cell injury was related to a high degree of inflammation, only some of which is an acutephase response due to tissue damage. The rise in fibrinogen was sustained, which might reflect low grade inflammation with long-term risk of thrombosis. The transient elevation of C-reactive protein levels might indicate a propensity to a pronounced inflammatory response and is associated with increased mortality.
Place, publisher, year, edition, pages
2003. Vol. 24, no 1, 86-93 p.
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:uu:diva-89549DOI: 10.1016/S0195-668X(02)00312-3PubMedID: 12559940OAI: oai:DiVA.org:uu-89549DiVA: diva2:161123